Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeSt trial in early rheumatoid arthritis
NL-OMON24149Active, not recruiting
- Sponsor
- Zorginstituut Nederland
- Start
- Mar 2000
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of methotrexate, prednisone, infliximab, hydroxychloroquine and 5-aminosalicylic acid + sulphasalazine in rheumatoid arthritis (RA) (4 arms), sponsored by Zorginstituut Nederland. Primary endpoints: Functional ability at 2 years and Radiographic joint damage at 2 years. Started Mar 2000; status: active, not recruiting.
02
Drugs
methotrexateprednisoneinfliximabhydroxychloroquine5-aminosalicylic acid + sulphasalazine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON24149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24149.